Safety Profile of GVHD Treatment Options

Discussing the key safety issues observed with ruxolitinib treatment in the REACH-3 trial and evaluating the risk/benefit profile for patients with steroid-refractory chronic GvHD.

EP: 1.Treatment Goals and Options for Chronic GvHD

EP: 2.Appropriateness of Initial Therapy for Chronic GvHD

EP: 3.Efficacy and Safety of Emerging Therapies

Now Viewing

EP: 4.Safety Profile of GVHD Treatment Options

EP: 5.Monitoring and Mitigating Adverse Events

EP: 6.Quality of Life Impact

EP: 7.Axatilimab Trial Results

EP: 8.Future Landscape of cGvHD Management

Recent Videos